A qualitative study of insurers' coverage for mifepristone-induced abortion

Managed Care Interface

Volumn 18, Issue 3, 2005, Pages

  Gemperli, Marcel P ^a,d   Stewart, Felicia H ^a   Phillips, Kathryn A ^b   Sakowski, Julie ^a   Van Bebber, Stephanie ^a   Bergthold, Linda ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Health Services Research and Health Economics

^c STANFORD UNIVERSITY   (United States)

^d USCF   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; MIFEPRISTONE; MISOPROSTOL;

ABORTION; ARTICLE; DIAGNOSTIC PROCEDURE; DRUG APPROVAL; DRUG COST; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INDUCED ABORTION; PREGNANCY TERMINATION; REIMBURSEMENT; THERAPEUTIC ABORTION; ECONOMICS; EMPIRICAL APPROACH; EVIDENCE BASED MEDICINE; FEMALE; GENETICS AND REPRODUCTION; INSURANCE; LEGAL ASPECT; PREGNANCY; QUALITATIVE RESEARCH; UNITED STATES;

EMPIRICAL APPROACH; GENETICS AND REPRODUCTION;

ABORTION, INDUCED; DRUG LABELING; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INSURANCE COVERAGE; MANAGED CARE PROGRAMS; MIFEPRISTONE; PREGNANCY; QUALITATIVE RESEARCH; UNITED STATES;

EID: 18244373473     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Joffe C, Weitz TA: Normalizing the exceptional: Incorporating the "abortion pill" into mainstream medicine. Soc Sci Med 2003;56:2353-2366.
2. Henshaw SK: Unintended pregnancy in the United States. Fam Plann Perspect 1998;30(1):24-29,46.
3. Boonstra H: Mifepristone in the United States: Status and future. The Guttmacher Report on Public Policy. 2002;5(3):4-7.
4. Finer LB, Henshaw SK: Abortion incidence and services in the United States in 2000. Perspect Sex Reprod Health 2003;35(1):6-15.
5. Zimmerman R: Insurers are likely to cover abortion pill - obstacles such as training and laws mean impact won't be immediate. Wall Street Journal October 2, 2000; A2.
6. Mifeprex (mifepristone) provider's agreement. U.S. Food and Drug Administration (ww.fda.gov/cder/drug/infopage/mifepristone/ prescriberagreement. pdf), September 2003.
7. Approval letter for mifepristone. U.S. Food and Drug Administration (www.fda.gov/cder/drug/infopage/mifepristone), September 2000.
8. Newhall EP, Winikoff B: Abortion with mifepristone and misoprostol: Regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol 2000;183(suppl 2):44-53.
9. World Health Organisation Task Force on Postovulatory Methods of Fertility Regulation: Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: A randomised trial. Br J Obstet Gynaecol 2000;107:524-530.
10. Ashok PW, Penney GC, Flett GM, et al: An effective regimen for early medical abortion: A report of 2000 consecutive cases. Hum Reprod 1998;13;2962-2965.
11. Schaff EA, Fielding SL, Eisinger SH, et al: Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 2000;61(1):41-46.
12. Schaff EA, Eisinger SH, Stadalius LS, et al: Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception 1999;59(1):1-6.
13. Schaff EA, Fielding SL, Westhoff C, et al: Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMA 2000;284:1948-1953.
14. Schaff EA, Stadalius LS, Eisinger SH, et al: Vaginal misoprostol administered at home after mifepristone (RU-486) for abortion. J Fam Pract 1997;44:353-360.
15. Stewart FH, Wells ES, Flinn SK, et al: Early Medical Abortion: Issues for Practice. San Francisco, UCSF Center for Reproductive Health Research and Policy, 2001.
16. el-Refaey H, Rajasekar D, Abdalla M, et al: Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995;332:983-987.
17. Safe Abortion: Technical and Policy Guidance for Health Systems. Geneva, Switzerland, World Health Organization, 2003.
18. Royal College of Obstetricians and Gynaecologists: The Care of Women Requesting Induced Abortion: National Evidence-Based Guidelines No. 7. London, UK. Royal College of Obstetricians and Gynaecologists, 2000; 37-39.
19. Clinical Policy Guidelines. Washington, DC, National Abortion Federation, 2003; 7-9.
20. Henshaw SK, Finer LB: The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health 2003;35(1):16-24.
21. Use of approved drugs for unlabeled indications. FDA Bull 1982;12(1):4-5.
22. State health facts online. Kaiser Family Foundation, Menlo Park, California (www.statehealthfacts.kff.org/), September 2003.
23. Competitive Edge HMO Directory: 2000. St. Paul, InterStudy, 2000.
24. Directory of Health Plans: 2000. Washington, DC, American Association of Health Plans, 2000.